-
Evenity®
Evenity® (romosozumab-aqqg) is an advanced bone-building therapy designed to help patients with osteoporosis increase bone density and reduce the risk of fractures. For individuals at high risk for fracture due to low bone mass or previous osteoporotic fractures, Evenity® provides targeted support to strengthen bones and protect long-term mobility.
At Singlepoint Healthcare, Evenity® is administered in a safe, comfortable, and closely monitored environment, with personalized care tailored to each patient’s bone health needs.
How Evenity® Works
Evenity® is a monoclonal antibody that stimulates new bone formation while simultaneously slowing bone breakdown. It targets the protein sclerostin, which naturally inhibits bone growth. By blocking sclerostin, Evenity® promotes the formation of stronger, denser bones, helping reduce fracture risk in the spine and other vulnerable areas.
Patients receiving Evenity® often experience improved bone density and enhanced skeletal strength over time, which support mobility, reduce fracture risk, and contribute to a more active, independent lifestyle.
Key Details
Important Information
| Category | Details |
|---|---|
| Conditions It Treats | Osteoporosis |
| Manufacturer | Amgen Inc. / UCB, Inc. |
| Administered by | Injection |
| Frequency | Once a month for 12 months |
| Length of Infusion | ~1–2 minutes |
| FDA Approval(s) | Postmenopausal Osteoporosis: Approved April 9, 2019 |